Pacira BioSciences Analyst Ratings
Truist Financial Downgrades Pacira BioSciences(PCRX.US) to Sell Rating, Announces Target Price $8
Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
Pacira Pharmaceuticals (PCRX) Gets a Hold From Barclays
Pacira Downgraded by J.P. Morgan, Piper, RBC, Raymond James
Piper Sandler Downgrades Pacira BioSciences to Neutral From Overweight, Adjusts Price Target to $11 From $42
Pacira BioSciences Analyst Ratings
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
Pacira BioSciences Price Target Cut to $37.00/Share From $42.00 by RBC Capital
Raymond James Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $37
A Quick Look at Today's Ratings for Pacira BioSciences(PCRX.US), With a Forecast Between $37 to $43
RBC Lowers Price Target on Pacira BioSciences to $37 From $42, Keeps Outperform Rating
Pacira BioSciences Analyst Ratings
Barclays Issues a Hold Rating on Pacira Pharmaceuticals (PCRX)
Pacira BioSciences Analyst Ratings
Truist Cuts Price Target on Pacira BioSciences to $30 From $45, Keeps Buy Rating
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Announces Target Price $30
Barclays Downgrades Pacira BioSciences to Equalweight From Overweight, Adjusts Price Target to $25 From $38
Pacira BioSciences Analyst Ratings
No Data